Kenvue Inc. (NYSE:KVUE) Position Lowered by Haverford Trust Co

Haverford Trust Co reduced its position in Kenvue Inc. (NYSE:KVUE) by 1.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 436,417 shares of the company’s stock after selling 4,736 shares during the quarter. Haverford Trust Co’s holdings in Kenvue were worth $9,318,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Corebridge Financial Inc. lifted its holdings in Kenvue by 4.2% in the fourth quarter. Corebridge Financial Inc. now owns 525,602 shares of the company’s stock worth $11,222,000 after acquiring an additional 21,209 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Kenvue by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company’s stock worth $4,665,908,000 after purchasing an additional 1,636,741 shares during the period. LPL Financial LLC lifted its holdings in shares of Kenvue by 4.9% in the 4th quarter. LPL Financial LLC now owns 2,064,405 shares of the company’s stock worth $44,075,000 after purchasing an additional 96,030 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in Kenvue during the 4th quarter valued at approximately $14,779,000. Finally, Sei Investments Co. grew its stake in Kenvue by 1.0% during the 4th quarter. Sei Investments Co. now owns 2,207,060 shares of the company’s stock worth $47,121,000 after buying an additional 20,802 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

KVUE has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. Royal Bank of Canada reiterated a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. Canaccord Genuity Group increased their price objective on Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. UBS Group reduced their price target on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Finally, Citigroup lowered their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $23.75.

Kenvue Price Performance

KVUE opened at $23.34 on Monday. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $44.61 billion, a P/E ratio of 44.04, a PEG ratio of 2.62 and a beta of 1.25. The stock has a fifty day moving average of $22.08 and a 200-day moving average of $22.43.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were issued a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.51%. Kenvue’s dividend payout ratio is 154.72%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.